| 1 |
Papavasileiou G, Tsilingiris D, Spyrou N, Vallianou NG, Karampela I, Magkos F, Dalamaga M. Obesity and main urologic cancers: Current systematic evidence, novel biological mechanisms, perspectives and challenges. Semin Cancer Biol 2023;91:70-98. [PMID: 36893965 DOI: 10.1016/j.semcancer.2023.03.002] [Reference Citation Analysis]
|
| 2 |
Tseng C. The Risk of Age-Related Macular Degeneration Is Reduced in Type 2 Diabetes Patients Who Use Metformin. Pharmaceuticals 2023;16:224. [DOI: 10.3390/ph16020224] [Reference Citation Analysis]
|
| 3 |
Tseng CH. Metformin Reduces the Risk of Hearing Loss: A Retrospective Cohort Study. Otolaryngol Head Neck Surg 2023. [PMID: 36939574 DOI: 10.1002/ohn.232] [Reference Citation Analysis]
|
| 4 |
Søndergaard CS, Esquivel PN, Dalamaga M, Magkos F. Use of Antihyperglycemic Drugs and Risk of Cancer in Patients with Diabetes. Curr Oncol Rep 2023;25:29-40. [PMID: 36445570 DOI: 10.1007/s11912-022-01344-7] [Reference Citation Analysis]
|
| 5 |
Tseng C. Metformin and risk of gingival/periodontal diseases in diabetes patients: A retrospective cohort study. Front Endocrinol 2022;13:1036885. [DOI: 10.3389/fendo.2022.1036885] [Reference Citation Analysis]
|
| 6 |
Tseng C. Metformin’s effects on varicocele, erectile dysfunction, infertility and prostate-related diseases: A retrospective cohort study. Front Pharmacol 2022;13:799290. [DOI: 10.3389/fphar.2022.799290] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 7 |
Tseng CH. Metformin and Risk of Malignant Brain Tumors in Patients with Type 2 Diabetes Mellitus. Biomolecules 2021;11:1226. [PMID: 34439890 DOI: 10.3390/biom11081226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 8 |
Abdelrahman S, Alghrably M, Campagna M, Hauser CAE, Jaremko M, Lachowicz JI. Metal Complex Formation and Anticancer Activity of Cu(I) and Cu(II) Complexes with Metformin. Molecules 2021;26:4730. [PMID: 34443319 DOI: 10.3390/molecules26164730] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 9 |
Tseng CH. The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature. Biomolecules 2021;11:1022. [PMID: 34356646 DOI: 10.3390/biom11071022] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Mitchell A, Price M, Cipriano G. The Prevention and Control of Cancer by Metformin in Patients with Type 2 Diabetes: A Systematic Mapping Review.. [DOI: 10.1101/2021.06.04.21258310] [Reference Citation Analysis]
|
| 11 |
Hu SL. The Nephrologist's Management of Renal Cell Carcinoma After Kidney Surgery. Semin Nephrol 2020;40:59-68. [PMID: 32130967 DOI: 10.1016/j.semnephrol.2019.12.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 12 |
Marquardt A, Solimando AG, Kerscher A, Bittrich M, Kalogirou C, Kübler H, Rosenwald A, Bargou R, Kollmannsberger P, Schilling B, Meierjohann S, Krebs M. Subgroup-Independent Mapping of Renal Cell Carcinoma-Machine Learning Reveals Prognostic Mitochondrial Gene Signature Beyond Histopathologic Boundaries. Front Oncol 2021;11:621278. [PMID: 33791209 DOI: 10.3389/fonc.2021.621278] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 10.0] [Reference Citation Analysis]
|
| 13 |
Halamkova J, Kazda T, Pehalova L, Gonec R, Kozakova S, Bohovicova L, Slaby O, Demlova R, Svoboda M, Kiss I. The Impact of Diabetes Mellitus on the Second Primary Malignancies in Colorectal Cancer Patients. Front Oncol 2020;10:573394. [PMID: 33585194 DOI: 10.3389/fonc.2020.573394] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 14 |
Undzyte G, Patasius A, Linkeviciute-Ulinskiene D, Zabuliene L, Stukas R, Dulskas A, Smailyte G. Increased kidney cancer risk in diabetes mellitus patients: a population-based cohort study in Lithuania. Aging Male 2020;23:1241-5. [PMID: 32342709 DOI: 10.1080/13685538.2020.1755249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 15 |
Zou Y, Hu C. A 14 immune-related gene signature predicts clinical outcomes of kidney renal clear cell carcinoma. PeerJ 2020;8:e10183. [PMID: 33194402 DOI: 10.7717/peerj.10183] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 16 |
Tseng CH. Metformin and Biliary Tract Cancer in Patients With Type 2 Diabetes. Front Oncol 2020;10:587666. [PMID: 33194743 DOI: 10.3389/fonc.2020.587666] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 17 |
Zajda A, Huttunen KM, Sikora J, Podsiedlik M, Markowicz-piasecka M. Is metformin a geroprotector? A peek into the current clinical and experimental data. Mechanisms of Ageing and Development 2020;191:111350. [DOI: 10.1016/j.mad.2020.111350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 18 |
Zhang K, Bai P, Dai H, Deng Z. Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Prim Care Diabetes 2021;15:52-8. [PMID: 32605879 DOI: 10.1016/j.pcd.2020.06.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 19 |
Pan Q, Lu X, Zhao C, Liao S, Chen X, Guo F, Yang C, Liu HF. Metformin: the updated protective property in kidney disease. Aging (Albany NY) 2020;12:8742-59. [PMID: 32364526 DOI: 10.18632/aging.103095] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
|
| 20 |
Nayan M, Punjani N, Juurlink DN, Finelli A, Austin PC, Kulkarni GS, Uleryk E, Hamilton RJ. Metformin Use and Kidney Cancer Survival Outcomes: A Systematic Review and Meta-Analysis. American Journal of Clinical Oncology 2019;42:275-84. [DOI: 10.1097/coc.0000000000000512] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Wei M, Mao S, Lu G, Li L, Lan X, Huang Z, Chen Y, Zhao M, Zhao Y, Xia Q. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal. BMC Cancer 2018;18:434. [PMID: 29665787 DOI: 10.1186/s12885-018-4344-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 22 |
Tseng CH. Metformin and lung cancer risk in patients with type 2 diabetes mellitus. Oncotarget 2017;8:41132-42. [PMID: 28456789 DOI: 10.18632/oncotarget.17066] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 6.4] [Reference Citation Analysis]
|
| 23 |
Laskar J, Bhattacharjee K, Sengupta M, Choudhury Y. Anti-Diabetic Drugs: Cure or Risk Factors for Cancer? Pathol Oncol Res 2018;24:745-55. [DOI: 10.1007/s12253-018-0402-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 24 |
Tseng CH. Metformin use and cervical cancer risk in female patients with type 2 diabetes. Oncotarget 2016;7:59548-55. [PMID: 27486978 DOI: 10.18632/oncotarget.10934] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 25 |
Tseng CH. Metformin reduces gastric cancer risk in patients with type 2 diabetes mellitus. Aging (Albany NY). 2016;8:1636-1649. [PMID: 27587088 DOI: 10.18632/aging.101019] [Cited by in Crossref: 47] [Cited by in F6Publishing: 52] [Article Influence: 7.8] [Reference Citation Analysis]
|
| 26 |
Tseng CH. Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus. Oncotarget 2017;8:18802-10. [PMID: 27861146 DOI: 10.18632/oncotarget.13390] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 27 |
Liu F, Yan L, Wang Z, Lu Y, Chu Y, Li X, Liu Y, Rui D, Nie S, Xiang H. Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: A systematic review and meta-analysis. Oncotarget. 2017;8:16017-16026. [PMID: 27926481 DOI: 10.18632/oncotarget.13762] [Cited by in Crossref: 53] [Cited by in F6Publishing: 59] [Article Influence: 8.8] [Reference Citation Analysis]
|
| 28 |
Zhao Y, Wang Y, Lou H, Shan L. Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Oncotarget 2017;8:81027-39. [PMID: 29113364 DOI: 10.18632/oncotarget.17515] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 29 |
Li Y, Hu L, Xia Q, Yuan Y, Mi Y. The impact of metformin use on survival in kidney cancer patients with diabetes: a meta-analysis. Int Urol Nephrol 2017;49:975-81. [PMID: 28271326 DOI: 10.1007/s11255-017-1548-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 30 |
Shah RR. Comment on: Bono P, Oudard S, Bodrogi I, et al. Outcomes in Patients With Metastatic Renal Cell Carcinoma Who Develop Everolimus-Related Hyperglycemia and Hypercholesterolemia: Combined Subgroup Analyses of the RECORD-1 and REACT Trials. Clin Genitourin Cancer 2016. Clinical Genitourinary Cancer 2017;15:e53-4. [DOI: 10.1016/j.clgc.2016.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 31 |
Shah RR. Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity? Drug Saf 2017;40:211-28. [DOI: 10.1007/s40264-016-0485-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 32 |
Pourfarjam Y, Rezagholizadeh L, Nowrouzi A, Meysamie A, Ghaseminejad S, Ziamajidi N, Norouzi D. Effect of Cichorium intybus L. seed extract on renal parameters in experimentally induced early and late diabetes type 2 in rats. Ren Fail 2017;39:211-21. [PMID: 27846769 DOI: 10.1080/0886022X.2016.1256317] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 33 |
Rhee CM, Kovesdy CP, Kalantar-Zadeh K. Risks of Metformin in Type 2 Diabetes and Chronic Kidney Disease: Lessons Learned from Taiwanese Data. Nephron 2017;135:147-53. [PMID: 27760420 DOI: 10.1159/000450862] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 34 |
Chen Y, Du L, Li L, Ma J, Geng X, Yao X, Liu G, Sun X. Cancer risk of sulfonylureas in patients with type 2 diabetes mellitus: A systematic review. J Diabetes 2017;9:482-94. [PMID: 27273872 DOI: 10.1111/1753-0407.12435] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 35 |
Tseng C. Response to Letter to the Editor on comments on Use of metformin and risk of kidney cancer in patients with type 2 diabetes Chin-Hsiao Tseng, Eur J Cancer, 2016, No. 52, pp. 19–25. European Journal of Cancer 2016;61:159-60. [DOI: 10.1016/j.ejca.2016.03.064] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 36 |
de Jong RG, Nielen JT, Masclee AA, Janssen-Heijnen ML, de Vries F. Comments on "Use of metformin and risk of kidney cancer in patients with type 2 diabetes", Chin-Hsiao Tseng, Eur J Cancer, 2016, No. 52, pp. 19-25. Eur J Cancer 2016;61:157-8. [PMID: 27131610 DOI: 10.1016/j.ejca.2016.03.065] [Reference Citation Analysis]
|
| 37 |
Sayyid RK, Fleshner NE. Diabetes Mellitus Type 2: A Driving Force for Urological Complications. Trends Endocrinol Metab 2016;27:249-61. [PMID: 26969242 DOI: 10.1016/j.tem.2016.02.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 38 |
Dmoszyńska A, Podhorecka M, Giannopoulos K. Metformina: stary lek w nowej aplikacji. Acta Haematologica Polonica 2016;47:139-145. [DOI: 10.1016/j.achaem.2016.04.001] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
